Does Medicare Cover Wegovy, Ozempic, and GLP-1 Weight Loss Drugs in 2026?

Quick answer

Does Medicare cover Wegovy? Not under regular Medicare Part D when it is prescribed only for weight loss, as of September 2026, because federal law lets Part D exclude "agents when used for anorexia, weight loss, or weight gain." What changed on July 1, 2026 is a temporary federal demonstration, the Medicare GLP-1 Bridge, which gives eligible Part D beneficiaries Wegovy (pen or tablet), the Zepbound KwikPen, or Foundayo for a $50 copay per one-month supply through December 31, 2027. Ozempic is not on the Bridge list and is not covered for weight loss, though a Part D plan may cover it for its labeled type 2 diabetes uses under that plan's formulary and prior authorization rules. Compounded GLP-1 products are not covered at all. CMS decides eligibility through a prior authorization, so nothing here is a guarantee of coverage.

What is the Medicare GLP-1 Bridge and how long does it last?

CMS describes the Bridge as "a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027." It runs in all states and U.S. territories and sits outside the normal Part D benefit: your drug plan does not review, approve, or pay for a Bridge prescription, and a single central processor working for CMS handles the prior authorization, the pharmacy claim, and payment. You do not enroll; your prescriber and pharmacy trigger it. Because it is a demonstration rather than a change to the Part D statute, the weight-loss exclusion itself is untouched.

Who qualifies for the Medicare GLP-1 Bridge?

Medicare.gov walks visitors through the same five questions as a self-check. Every answer has to go your way: (1) Do you have Medicare drug coverage through an eligible plan type? (2) Are you already getting a GLP-1 through your Part D plan? (3) Do you have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease? (4) Are you 18 or older? (5) Which BMI band were you in when you started a GLP-1 (use the BMI calculator)? In detail:

1. You have Medicare drug coverage (Part D) through an eligible plan type (see the Medicare Advantage section below).
2. You are not already getting a GLP-1 through your Part D plan.
3. You do not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. CMS routes those diagnoses to regular Part D coverage, "even if they otherwise meet the Medicare GLP-1 Bridge clinical criteria."
4. You are 18 or older and, when you started GLP-1 therapy, at least one of these applied:

• a BMI of 35 or higher;
• a BMI of 30 or higher plus diastolic heart failure (heart failure with preserved ejection fraction), high blood pressure that stays uncontrolled despite two blood pressure medicines, or chronic kidney disease at stage 3a or higher;
• a BMI of 27 or higher plus prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms.

The criteria are measured when you first started a GLP-1, not when the request is filed: CMS gives the example of a person who began therapy in September 2024 with a BMI of 37 and has a BMI of 34 at a July 2026 request, who still qualifies on the BMI 35 tier. Your prescriber must also certify that the drug is part of a lifestyle program focused on diet and exercise. A BMI calculator gives you the number to bring to the visit. Only CMS decides eligibility.

Which GLP-1 drugs does the Bridge cover, and which forms are left out?

CMS updated the list on April 6, 2026 to add Foundayo and to clarify that only the KwikPen formulation of Zepbound is included; pen needles for the KwikPen are not covered by the Bridge or by your Part D plan. Compounded medications are not FDA-approved as final products, and the FDA states that it "does not review compounded drugs for safety, effectiveness or quality before they are marketed."

What is the Medicare Wegovy $50 copay under the Bridge, and what does it not do?

As of September 2026, an eligible beneficiary pays a $50 copayment to the pharmacy for a one-month supply, which Medicare.gov defines as "either 28 or 30 days, depending on drug." The $50 is the same regardless of income.

Because the Bridge is a separate program, Medicare.gov is explicit about what the copay does not do. It does not count toward your Part D deductible or out-of-pocket limit. It will not appear on your Part D Explanation of Benefits or on a Medicare Summary Notice. It cannot be lowered by Extra Help. It cannot be spread across months with the Medicare Prescription Payment Plan.

How do I get Medicare to pay for Wegovy?

There is no patient application. The sequence, as CMS and Medicare.gov describe it:

1. Talk with your doctor. If a covered GLP-1 is appropriate, your prescriber sends the prescription to your pharmacy.
2. The pharmacy submits the claim first. CMS tells prescribers not to file the prior authorization before the pharmacy claim, because doing so returns a "patient not found" error. The pharmacy sends the request to your prescriber, typically within 24 to 72 hours.
3. Your prescriber completes the prior authorization, attesting under penalty of perjury that you meet the criteria. No Part D denial is required first, and the prescriber need not be enrolled in Medicare, though they must not be on the CMS Preclusion List.
4. A decision is issued within 72 hours and mailed to you; if approved, the letter says your GLP-1 is covered under the Bridge. There is no appeals process, but a prescriber can resubmit with corrected information.
5. Give the pharmacist your Medicare Number from your Medicare card, not your Part D plan ID. The pharmacy may also ask for the last four digits of your Social Security Number; report suspected fraud to 1-800-MEDICARE (1-800-633-4227).

Once approved, the prior authorization stays valid "including for refills and dose changes" through December 31, 2027, unless you change GLP-1s. If the pharmacy cannot get the product, the guide on what to do when a pharmacy cannot fill Wegovy covers transfers. Prescribers can call the Bridge call center at 855-273-0102.

Does Medicare Advantage cover Wegovy?

It depends on the plan type, not the insurer. Medicare.gov lists the eligible plan types as a standalone Part D plan (PDP); a Medicare Advantage coordinated care plan with drug coverage, meaning HMO, HMOPOS, and local and regional PPO plans (MA-PD); a Special Needs Plan (SNP); an employer or union group waiver plan (EGWP); and the Limited Income Newly Eligible Transition (LI NET) program.

CMS lists who is out: people whose only coverage is a private fee-for-service plan, a cost plan, a health care prepayment plan, or a PACE organization, "unless also enrolled in a standalone PDP." A Medicare Advantage plan without drug coverage does not qualify on its own; dually eligible beneficiaries in an eligible plan type do. Outside the Bridge, an MA-PD drug benefit follows the Part D rules below.

Why doesn't regular Medicare Part D cover weight-loss drugs?

Because Congress wrote the exclusion into the Part D statute. 42 U.S.C. 1395w-102(e)(2)(A) says a covered Part D drug "does not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1396r-8(d)(2)" as those sections "were in effect on December 8, 2003." That cross-referenced Medicaid list, at 42 U.S.C. 1396r-8(d)(2)(A), begins with "Agents when used for anorexia, weight loss, or weight gain."

The exclusion attaches to the use, not the molecule, so the same drug can be a covered Part D drug when prescribed for a medically accepted indication that is not on the excluded list. That door opened in 2024, when the FDA added a cardiovascular indication to Wegovy and, as KFF reported, CMS told Part D plans they could add it to formularies "now that it has a medically-accepted indication that is not specifically excluded from Medicare coverage." KFF estimated, from 2020 data, that about 3.6 million Medicare beneficiaries had established cardiovascular disease and obesity or overweight and could fit that door.

When does Part D cover Wegovy, Ozempic, Zepbound or Saxenda without the Bridge?

When the prescription is for a labeled indication other than the excluded weight-loss use, and your plan's formulary and prior authorization rules allow it. By label, as of September 2026:

• Wegovy (semaglutide) injection: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; weight management; and, on the current DailyMed label, noncirrhotic MASH with moderate to advanced liver fibrosis in adults under accelerated approval.
• Wegovy tablets: the cardiovascular risk-reduction indication and weight management in adults.
• Ozempic (semaglutide) injection: glycemic control in adults with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease; and kidney and cardiovascular risk reduction in adults with type 2 diabetes and chronic kidney disease. No weight-management indication.
• Zepbound (tirzepatide): weight management, and moderate to severe obstructive sleep apnea in adults with obesity.
• Mounjaro (tirzepatide): type 2 diabetes only.
• Saxenda (liraglutide) and Foundayo (orforglipron): weight management only, so no Part D door outside the exclusion. Saxenda is also not on the Bridge list.

CMS confirms that "type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) indications are eligible for Part D coverage." Heart disease overlaps: the Bridge tiers include a prior heart attack or stroke, but a prescription written "to reduce the risk of major adverse cardiovascular events" is routed to the Part D plan, not the Bridge.

Does Medicare cover Ozempic?

For its labeled uses, it may be, subject to your plan's rules; for weight loss, no. Ozempic is labeled for type 2 diabetes and for cardiovascular and kidney risk reduction in people with type 2 diabetes, so a Part D plan may cover it for those diagnoses, often with prior authorization. It has no weight-management indication and is not on the Bridge list; the same is true of Mounjaro.

Will Medicare pay for Wegovy pills in 2026?

For eligible Bridge participants, yes: CMS lists "Wegovy (injection and tablets)" and states that "all formulations of Wegovy" are available through the program, with the tablet NDCs on its published list. The tablet carries the same two adult indications as the injection on the current DailyMed label, cardiovascular risk reduction and weight management. A month of tablets is one bottle of 30, at the same $50 copay as the pen.

How do I check whether my Part D plan covers a GLP-1?

Medicare.gov explains that "a plan's list of covered drugs is called a formulary, and each plan has its own formulary." The official comparison tool is the Medicare Plan Finder at medicare.gov/plan-compare, where you enter your drugs and pharmacy and see each plan's coverage and estimated cost. Then read the plan rules: prior authorization, step therapy (trying a less expensive drug first), and quantity limits.

Two protections matter here. When new drug coverage begins, you may get a transition fill, "a one-time, 30-day supply of a drug you've been taking that your plan either doesn't cover or requires prior authorization/step therapy." And you or your prescriber can ask the plan for an exception to any of these rules, backed by a supporting statement from your prescriber.

What if my plan stopped covering Wegovy, or I do not qualify for the Bridge?

Work through these routes in order.

Ask about a covered indication. If you have type 2 diabetes, established cardiovascular disease, sleep apnea, or MASH, the Part D door above may apply. For 2026, NovoCare summarizes the standard Part D benefit as a $615 deductible, then 25% coinsurance until you reach $2,100 out of pocket, then $0 for the rest of the year, as of September 2026; Extra Help lowers these amounts for people who qualify (NovoCare's Medicare page lists the 2026 Extra Help and dual-eligible copay tiers, as of September 2026), and the Medicare Prescription Payment Plan spreads them across the year without lowering them.

Request a transition fill or an exception if a formulary change caught you mid-treatment.

Check whether you qualify for the Bridge if your use is weight-only. A plan dropping coverage does not disqualify you; currently receiving a plan-paid GLP-1 does.

Compare cash prices from government and manufacturer pages. As of September 2026, TrumpRx.gov lists the Wegovy pill at $149 a month, the Wegovy pen at $199 a month, Ozempic at $199 a month and Zepbound at $299 a month, against list prices of $1,349, $1,349, $1,028 and $1,087; the full price ladder is in how much Wegovy costs. Medicare.gov cautions that TrumpRx and discount cards "aren't considered creditable coverage" and do not count toward your Medicare deductible or out-of-pocket maximum. The "Wegovy for $25" people mention is the Wegovy Savings Offer for commercial insurance; its terms state "Government beneficiaries excluded," so as of September 2026 it is not available to anyone on Medicare.

Compounded semaglutide or tirzepatide is a separate cash-pay category outside Medicare. Compounded medications are not FDA-approved as final products, Medicare does not cover them, and they are not on the Bridge list. Read whether insurance covers compounded GLP-1 medications before weighing that route.

Separately, Part B covers obesity screening and behavioral counseling in a primary care setting for people with a BMI of 30 or more, at no cost if the provider accepts assignment. Medicare.gov also states that Medicare "covers some bariatric surgical procedures (like gastric bypass surgery and laparoscopic banding surgery) if you're eligible," under Part B, with costs that vary by situation.

What happens when the Medicare GLP-1 Bridge ends in December 2027?

CMS has said two things and nothing more. The Bridge "has been extended through December 31, 2027," and the BALANCE Model, under which CMS would negotiate GLP-1 prices for Part D plans, is not launching in Medicare in 2027; the extension lets CMS "collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D." No coverage for weight-only use after that date has been announced, and a Bridge prior authorization ends with the program.

What should I ask my Part D plan before deciding?

1. Am I in an eligible plan type for the Medicare GLP-1 Bridge?
2. Does my plan cover any GLP-1 for a condition I have, such as type 2 diabetes, heart disease, sleep apnea or MASH, and what prior authorization or step therapy applies?
3. What is my actual copay or coinsurance on the covered product, and which benefit phase am I in?
4. What is my total out-of-pocket cost over a full year, given that the $50 Bridge copay does not count toward my out-of-pocket limit?

Nothing here replaces a call to your plan or to 1-800-MEDICARE, and only CMS decides Bridge eligibility. Related questions on the Zepbound KwikPen and other coverage topics are answered in the help center.

This article is for informational purposes only and does not constitute medical advice. Medication is prescribed only if a licensed physician determines it is appropriate. Medicare rules change and depend on your plan; confirm details at Medicare.gov or with your plan. This information is not a guarantee of coverage.

Telehealth prescribing rules differ by state. Read the state-by-state guide.